|
|
|
|
| LEADER |
04910nam a2200661 4500 |
| 001 |
ocn729726279 |
| 003 |
OCoLC |
| 005 |
20170124072404.9 |
| 006 |
m o d |
| 007 |
cr cn||||||||| |
| 008 |
110609s2011 gw a ob 001 0 eng d |
| 040 |
|
|
|a DG1
|b eng
|e rda
|e pn
|c DG1
|d YDXCP
|d CDX
|d OCLCQ
|d E7B
|d N$T
|d SCB
|d OCLCQ
|d MHW
|d OTZ
|d IDEBK
|d OCLCQ
|d NLGGC
|d OCLCQ
|d COO
|d OCLCQ
|d TMC
|d D6H
|d GrThAP
|
| 019 |
|
|
|a 740225701
|a 741454003
|a 778454561
|a 781264224
|a 785512762
|a 816845214
|
| 020 |
|
|
|a 9783527635955
|q (electronic bk.)
|
| 020 |
|
|
|a 3527635955
|q (electronic bk.)
|
| 020 |
|
|
|a 9783527635979
|q (electronic bk.)
|
| 020 |
|
|
|a 3527635971
|q (electronic bk.)
|
| 020 |
|
|
|a 1283140918
|
| 020 |
|
|
|a 9781283140911
|
| 020 |
|
|
|z 9783527326969
|q (hbk.)
|
| 020 |
|
|
|z 3527326960
|q (hbk.)
|
| 020 |
|
|
|z 9783527635962
|
| 020 |
|
|
|z 3527635963
|
| 020 |
|
|
|z 9783527635986
|
| 020 |
|
|
|z 352763598X
|
| 024 |
8 |
|
|a 9786613140913
|
| 029 |
1 |
|
|a AU@
|b 000047551108
|
| 029 |
1 |
|
|a NZ1
|b 14693860
|
| 029 |
1 |
|
|a NZ1
|b 15915098
|
| 035 |
|
|
|a (OCoLC)729726279
|z (OCoLC)740225701
|z (OCoLC)741454003
|z (OCoLC)778454561
|z (OCoLC)781264224
|z (OCoLC)785512762
|z (OCoLC)816845214
|
| 037 |
|
|
|a 10.1002/9783527635955
|b Wiley InterScience
|n http://www3.interscience.wiley.com
|
| 050 |
|
4 |
|a RS431.A66
|b A68 2011
|
| 060 |
|
4 |
|a QV268.5
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.7924
|2 22
|
| 049 |
|
|
|a MAIN
|
| 245 |
0 |
0 |
|a Antiviral drug strategies /
|c edited by Erik De Clercq.
|
| 264 |
|
1 |
|a Weinheim :
|b Wiley-VCH ;
|a Chichester :
|b John Wiley [distributor],
|c 2011.
|
| 300 |
|
|
|a 1 online resource (xx, 406 pages) :
|b illustrations (some color).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Methods and principles in medicinal chemistry ;
|v v. 50
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|t Outlook of the antiviral drug era, now more than 50 years after description of the first antiviral drug /
|r Erik De Clercq --
|t Inhibition of HIV entry /
|r José A. Esté --
|t Targeting integration beyond strand transfer: development of second-generation HIV integrase inhibitors /
|r Arnout R.D. Voet,
|r Marc De Maeyer,
|r Frauke Christ,
|r Zeger Debyser --
|t From saquinavir to darunavir: the impact of 10 years of medicinal chemistry on a lethal disease /
|r Marie-Pierre de Béthune,
|r Anik Peeters,
|r Piet Wigerinck --
|t Acyclic and cyclic nucleoside phosphonates /
|r Richard L. Mackman,
|r Tomas Cihlar --
|t Helicase-primase inhibitors: a new approach to combat herpes simplex virus and varicella zoster virus /
|r Subhajit Biswas,
|r Hugh J. Field --
|t Cyclophilin inhibitors /
|r Grégoire Vuagniaux,
|r Arnaud Hamel,
|r Rafael Crabbé,
|r Hervé C. Porchet,
|r Jean-Maurice Dumont --
|t Alkoxyalkyl ester prodrugs of antiviral nucleoside phosphates and phosphonates /
|r James R. Beadle,
|r Karl Y. Hostetler --
|t Maribavir: a novel benzimidazole ribonucleoside for the prevention and treatment of cytomegalovirus diseases /
|r Karen K. Biron --
|t Anti-HCMV compounds /
|r Graciela Andrei,
|r Robert Snoeck --
|t Lethal mutagenesis as an unconventional approach to combat HIV /
|r Pinar Iyidogan,
|r Karen S. Anderson --
|t Recent progress in the development of HCV protease inhibitors /
|r Nagraj Mani,
|r Bhisetti G. Rao,
|r Tara L. Kieffer,
|r Ann D. Kwong --
|t Antiviral RNAi: how to silence viruses /
|r Karin J. von Eije,
|r Ben Berkhout --
|t Neuraminidase inhibitors as anti-influenza agents /
|r Willard Lew,
|r Michael Z. Wang,
|r Xiaowu Chen,
|r James F. Rooney,
|r Choung Kim --
|t From TIBO to rilpivirine: the chronicle of the discovery of the ideal nonnucleoside reverse transcriptase inhibitor /
|r Erik De Clercq.
|
| 588 |
0 |
|
|a Print version record.
|
| 520 |
|
|
|a By focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, this ready reference provides the critical knowledge needed to develop entirely novel therapeutics and to target new viruses. It begins with a general discussion of antiviral strategies, followed by a broad survey of known viral targets, such as reverse transcriptases, proteases, neuraminidases, RNA polymerases, helicases and primases, as well as their known inhibitors. The final section contains several cases studies of recent successful antiviral drug development. Edited by Erik de.
|
| 650 |
|
0 |
|a Antiviral agents
|x Development.
|
| 650 |
|
4 |
|a Antiviral agents
|x Development.
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
2 |
|a Antiviral Agents.
|
| 650 |
|
2 |
|a Drug Discovery.
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a De Clercq, Erik.
|
| 776 |
0 |
8 |
|i Print version:
|t Antiviral drug strategies.
|d Weinheim : Wiley-VCH ; Chichester : John Wiley [distributor], 2011
|z 9783527326969
|w (OCoLC)664325845
|
| 830 |
|
0 |
|a Methods and principles in medicinal chemistry ;
|v v. 50.
|
| 856 |
4 |
0 |
|u https://doi.org/10.1002/9783527635955
|z Full Text via HEAL-Link
|
| 994 |
|
|
|a 92
|b DG1
|
